It is extremely encouraging that Summit has received regulatory approval to initiate PhaseOut DMD, a Phase II open label trial of SMT C1100 in Duchenne Muscular Dystrophy (DMD). SMT C1100, the group’s lead utrophin modulator programme for DMD, met its primary objective in its Phase Ib modified diet clinical trial in August and the approval to commence a Phase II proof of concept trial is an important milestone for the group in its development. There is currently no cure for DMD, a fatal muscle w ....
